The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3

作者：

Shafiq, Aimen ^{[1
]}

Mahboob, Eman ^{[1
]}

Samad, Muhammad Ammar ^{[1
]}

Rehman, Mohammad Hassam Ur ^{[1
]}

Tharwani, Zoaib Habib ^{[1
]}

机构：

[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan

来源：

ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷

关键词：

Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;

D O I：

10.1016/j.amsu.2022.104555

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.

引用

页数：6

共 50 条

[41] NAFLD prevalence in older patients with T2DM
Eleni Kotsiliti
Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
[42] ADA goals are attainable in patients with T2DM
Hood, Robert C.
DIABETES, 2006, 55 : A271 - A271
[43] Metformin safety in T2DM patients with psoriasis
Reactions Weekly, 2019, 1743 (1) : 10 - 10
[44] Duration of Depressive Disorders in Patients with T2DM
De Groot, Mary K.
Crick, Kent
Long, Molly
Shubrook, Jay
DIABETES, 2016, 65 : A217 - A217
[45] T2DM patients have low levels of physical activity: role of obesity
Fagour, C.
Pezzino, S.
Florenty, S.
Gonzalez, C.
Rosette-Narece, M.
Gin, H.
Rigalleau, V.
DIABETES & METABOLISM, 2011, 37 : A25 - A26
[46] Sex hormone levels are not associated with progression of renal disease in male patients with T2DM
Feigerlova, E.
Saulnier, P. -J.
Gourdy, P.
Roussel, R.
Halimi, J. -M.
Gand, E.
Dardari, D.
Guerci, B.
Sosner, P.
Marre, M.
Zaoui, P.
Ragot, S.
Hadjadj, S.
DIABETES & METABOLISM, 2017, 43 (02) : 140 - 145
[47] THE RELATIONSHIP BETWEEN LIPID PEROXIDATION MARKER AND RENAL FUNCTION IN INDONESIAN T2DM PATIENTS
Sauriasari, R.
Azizahwati
Andrajati, R.
Dharmeizar
Saputri, D. A.
Muris, R. U.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S130 - S130
[48] THE ROLE OF SGLT2 INHIBITORS IN THE MANAGEMENT OF T2DM
Jung, Chang Hee
JOURNAL OF HYPERTENSION, 2016, 34 : E186 - E186
[49] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
Lund, S.
Solimando, F.
Kohler, S.
Zeller, C.
Kaspers, S.
DIABETOLOGIA, 2016, 59 : S26 - S27
[50] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Vedel, Anita
Roux, Christiansen Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A280 - A280

← 1 2 3 4 5 →